BECTON DICKINSON & CO

BDX's capital structure is characterized by a debt-to-equity ratio of 0.67, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as high, but its current ratio of 1.05 is close to the minimum comfort range, suggesting potential near-term liquidity constraints. Free cash flow of $549 million in Q1 2026 supports operational flexibility, though cash and equivalents of $740 million are insufficient to cover long-term debt of $16.9 billion. Profitability metrics show a return on equity (ROE) of 1.51% and a return on assets (ROA) of 0.7%, both below the industry median for medical equipment firms. Operating income of $552 million and net income of $382 million reflect a net margin of 7.3%, which is in line with the sector average but lags behind top performers. The company's operating cash flow of $657 million supports its capital expenditure of $108 million, but the ROE suggests underutilization of equity capital. Geographically, BDX operates in a globally diversified manner, though revenue concentration data is not disclosed in the input. Segment-wise, the BD Medical Essentials segment is the largest contributor, followed by BD Connected Care, BD BioPharma Systems, and BD Interventional. The reorganization into five segments in October 2025 may improve operational clarity but could also introduce short-term reporting complexity. Growth trajectory is modest, with Q1 2026 revenue of $5.25 billion showing a year-over-year increase of 3.2%. Analysts project a mean price target of $194.26, with a median of $198.00, suggesting a 5.8% upside from the current price. The company's capital expenditure outlook is stable, with a focus on maintaining existing infrastructure rather than aggressive expansion. Risk factors include medium dilution potential, with 4,181 thousand share equivalents excluded from diluted earnings per share due to exercise prices exceeding the average market price. The company faces ongoing legal investigations, including civil investigative demands from the Department of Justice, which could result in material liabilities if unresolved. Additionally, the reorganization of segments may lead to short-term operational disruptions. Recent events include the adoption of new accounting standards for software costs and enhanced disclosures for income statement expenses. The company also reorganized its segments in October 2025, which may affect future financial reporting. These changes reflect a strategic shift toward operational transparency and alignment with evolving regulatory requirements.